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Abstract 
 
Nail-patella syndrome, also known as hereditary onycho-osteodystrophy, is a rare autosomal dominant disorder with 
pleiotropic phenotypic expression. 
The present report is of a nail-patella syndrome patient, a 26-year-old female, admitted to our NeuroMuscular Rehabilitation 
Clinic Division for neurological symptoms, secondary to a severe spondylolysthesis with bilateral L5 pedicle fracture. During 
hospitalization, she was also diagnosed with mild thyrotoxicosis, but interestingly enough, the bone mineral density, assessed at 
multiple sites, was quasi-normal. 
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Abbreviations 
BMD – bone mineral density, BMI – body mass index, DXA – dual-energy X-ray absorptiometry, FT4 – serum free thyroxin, HOOD – 
Hereditary onycho-osteodystrophy, NPS – Nail-patella syndrome, TSH – thyroid-stimulating hormone 
Introduction 
Nail-patella syndrome (NPS) also known as Fong 
disease, hereditary onycho-osteodystrophy (HOOD), 
Österreicher-Turner syndrome, or Turner-Kieser 
syndrome is a rare autosomal dominant condition, caused 
by anomalies of the LMX1B gene. Its incidence has been 
roughly estimated at 1: 50000 [1,2]. 
NPS is defined by three major features: 
  Nail anomalies – in 80-90% of patients [3]; 
they are bilateral and symmetrical; nails can 
be absent, hypoplastic, or dystrophic 
(discoloration, triangular lunulae, splitting, 
ridging, thinning) [4,2] 
  Skeletal anomalies – present in virtually all 
patients; the most frequent are: absent or 
hypoplastic patellae, iliac horns, dysplastic 
elbows [2,3,4] 
  Renal disease – found in approximately 40% 
of the NPS patients [5]:  proteinuria, 
microscopic hematuria, hypertension; 
progression to renal failure has been reported 
in 5-14% of NPS patients [2,3,5].  
There is a great inter- and intrafamilial variability of 
the NPS clinical manifestations and literature suggests it 
is common for the disorder to go undiagnosed for several 
generations in affected families [2]. 
Iliac horns, observed in up to 70% of the patients 
[1], are the patognomonic radiological features of the 
disorder. They are asymptomatic, symmetrical findings, 
consisting in bone spurs arising from the iliac crests, 
sometimes detectable on physical examination. 
The patellae may be absent or hypoplastic; 
fragmentation is frequent, resulting in lateral slippage 
during knee flexion [4,6]. Radial heads are often 
hypoplastic, causing subluxations of the elbow. 
Complications such as joint effusions and secondary 
arthrosis of the affected joints may cause pain and 
functional limitations. A wide range of other skeletal 
anomalies can be found (with lower frequency) in NPS 
patients: genu recurvatum, varum or valgum, hypoplasia 
of cruciate ligaments, pectus excavatum, scoliosis, 
increased lumbar lordosis, spondylolisthesis, 
spondylolysis, spina bifida, etc. [2] 
Other features described in NPS patients are: 
glaucoma [1], gastrointestinal symptoms (constipation, 
irritable bowel syndrome), lean habitus and difficulty to 
gain weight, depression, attention deficit disorder [2,7]. 
Though NPS is associated with multiple skeletal 
anomalies and often low body mass index (BMI), it has Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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not been proved to associate with severe decreases of 
bone mineral density (BMD). One report described a case 
of NPS with osteoporosis [8]. A clinical study found that 
NPS adult patients had a bone mineral density (BMD) 
lower than normal adults, but still, in the normal to 
osteopenic range; their results also showed a significantly 
higher prevalence of fractures among the NPS patients, 
generally occurring before puberty [9]. This may suggest 
that bone fragility in these patients may be due to other 
causes, such as altered quality of the matrix, or abnormal 
turnover [10]. 
Thyrotoxicosis has never been described as a 
feature of NPS and it was probably an incidental, non-
related finding in our patient. In this particular case, given 
her medical history of fractures, without a clear account of 
a previous significant trauma, the presence of 
thyrotoxicosis, a known risk factor for osteoporosis [11,12] 
, led us to further investigate the skeletal integrity. 
Case Report 
A 26-year-old female patient, previously diagnosed 
with NPS, was admitted to our clinic for neurologicall 
rehabilitation. She presented cauda equina syndrome, 
secondary to severe anterior spondylolysthesis of L5 on 
S1, which had been operated 3 times, with partial 
amendment of the neurological deficits.  
According to the patient, she had first developed 
severe low back pain in 2002, when she was diagnosed 
with anterior spondylolysthesis L5-S1 and bilateral 
fracture of the L5 pedicles; she was first operated in 2003 
(posterior spondylodesis with autologous bone graft and 
fixation with a plate and screw system); the neurological 
symptoms first occurred in 2005 (when the osteosynthesis 
material was extracted). In 2009, she experienced a 
worsening of the motor impairment, with the onset of 
urinary incontinence and underwent spinal surgery again 
(anterior spondylodesis with rib bone graft and fixation 
with a dual rod system). The existence of a traumatic 
precipitating factor, as well as the exact progression of 
her symptoms remained unclear. 
The chief complaints at admission were: 
paraplegia with L3 neurological level and moderate motor 
deficit, affecting predominantly the left lower limb, 
paresthesia in the left lower limb and urinary incontinence.  
Her medical history revealed: 
  Multiple drug allergies (nonsteroidal anti-
inflammatory drugs, metamizole, mepivacaine) 
  Allergic asthma 
  Hypoplasia of the sternal manubrium 
(diagnosed in 2010, by computed tomography) 
  Dislocatable left hip – operated in 2010 
  Dislocatable left patella – operated twice, in 
2003 and 2007 
  Severe chronic constipation 
Aside from the chief complaint, physical 
examination found multiple features associated with NPS, 
especially skeletal anomalies: 
  Asthenic habitus, BMI of 15,807 kg/m2 (with 
normal dietary intake) 
  Global, symmetrical muscle hypotrophy  
  Global joint hypermobility 
  Pectus excavatum (Figure 1) 
  Increased lumbar lordosis 
  Bilateral iliac horns (Figure 2) 
  Moderate left knee instability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The patient’s nails, surprisingly, showed no 
abnormalities.  
Ophthalmologic examination found bilateral 
hyperopic moderate astigmatism, but no glaucoma. 
Laboratory results were normal, except for a urinary tract 
infection, probably due to urinary incontinence and 
bladder catheterization. Repeated tests found no 
proteinuria. 
In addition, the physical examination found that the 
patient had warm, moist skin and a discrete tremor of the 
hands. This prompted us to assess the thyroid function. 
Fig. 1. Pectus excavatum 
Figure 2. Visible anterior iliac horn Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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The results showed a suppressed thyroid-stimulating 
hormone: TSH 0,252 μIU/ml (normal 0,4-4,70 μIU/ml), a 
high level of serum free thyroxin: FT4 26,3 pmol/l (normal 
10-23 pmol/l) and elevated thyroid antibodies: thyroid 
peroxidase antibodies 368,14 IU/ml (normal 0-5,61 IU/ml); 
thyroglobulin antibodies 31,12 IU/ml (normal 0-4,11 
IU/ml), leading to the diagnosis of thyrotoxicosis, probably 
of autoimmune etiology. 
Given the history of previous fractures, prolonged 
pain and motor impairment, resulting in mobility 
limitations, associated with the presence of thyrotoxicosis, 
we decided to further explore the bone mineral density of 
the patient. When informed about this test, she produced 
the results to a BMD DXA (dual-energy X-ray 
absorptiometry) investigation she had undertaken 3 
months before. As seen in Table 1, the T score values 
ranged from normal to mild osteopenia for all regions 
explored.  
 
Table 1. BMD – DXA assessment: detailed T score values. We 
did not consider the L4 vertebra a valid region for this test,since 
it had born a metal screw 
Region  T score 
(young adult) 
Z score 
(age-matched) 
Left femoral neck  -0,6  -0,1 
Right femoral neck  0,4  0,9 
Left Wards triangle  -0,2  0,2 
Right Wards triangle  0,0  0,4 
Left trochanter  -1,1  -0,5 
Right trochanter  -0,8  -0,2 
Left total hip  -0,8  -0,2 
Right total hip  -0,2  0,3 
L1  -1,2  0,4 
L2  -1,4  0,6 
L3  0,6  1,3 
L1-L2  -1,3  -0,5 
L1-L3  -0,5  0,3 
Discussion 
The gene implicated in NPS, LMX1B (LIM 
homeobox transcription factor 1-beta), is located on the 
long arm of chromosome 9 (9q34) [2,9]. It has been 
demonstrated that this transcription factor plays an 
important role in skeleton, kidney and eye development 
[2,13], but the full extent of LMX1B’s regulatory functions 
is still unclear. To date, more than 100 loss-of-function 
mutations of this gene have been identified in NPS 
patients [9,14,15]. 
Our patient was diagnosed with NPS in 2010. Her 
DNA sequence analysis showed a heterozygous 
missense mutation in exon 5 of LMX1B gene: c.713G>A 
(p.Arg238His), which had never been described before 
(GenBank Accession no NM_002316.2). Her mother was 
clinically diagnosed with NPS, having nail aplasia and a 
dysplastic patella, but no other manifestations. The lack of 
phonotypical similarity between daughter and mother is 
not surprising, given the important individual variability of 
NPS clinical features. 
Aside from the unusually severe, invalidating 
spondylolysthesis, accompanied by numerous other 
skeletal anomalies, the case was interesting because of 
the association with thyrotoxicosis and almost normal 
BMD. To date there is no evidence of this gene playing a 
role in the development of the hypothalamic pituitary 
thyroid axis, which is why we assumed this association 
was incidental. 
We initially inferred that the presence of 
osteoporosis was highly probable in this patient for 
several reasons: 
  NPS, a disorder affecting the limb 
development may interfere with bone 
mineralization 
  Extensive anamnesis did not reveal a clear 
traumatic cause for the pedicle fractures 
  The patient had a history of prolonged (about 
8 years) severe pain, motor impairment, 
repeated surgical interventions, that had 
significantly limited her physical activities 
  The patient also had thyrotoxicosis with an 
undetermined duration; adult thyrotoxic 
patients generally have an increased bone 
turnover [11], with a tendency to bone loss, 
probably due to accelerated resorption, not 
compensated by a similar increase in bone 
formation [12] 
  She had a significantly low BMI, which 
according to her account was not due to a 
recent loss of weight 
BMD assessment by DXA contradicted this 
hypothesis. We only found values of the T score 
consistent with mild osteopenia in the lumbar spine (L1-
L2). Interesting findings were the lower values of the T 
score in the left hip, in comparison to the right one; this 
correlated with the severity of the motor impairment, 
which was more pronounced in the left lower limb. 
Therefore, it seems logical to assume that the (mild) 
decrease in BMD seen in this patient had the limitation of 
physical activity as main etiological mechanism, and not 
thyrotoxicosis or the underlying genetic condition.  
Since the patient was young, with no sign of renal 
involvement or cardio-respiratory dysfunction, our 
objectives were to improve her neurolocomotor 
performance and enhance her autonomy. We fitted her 
with a textile brace for the left knee, a left ankle-foot 
orthosis and a contralateral Canadian crutch. Since her 
spine was surgically stabilized, she has undergone a 
complete kynesitherapy program. We started her on 
intermittent catheterization, to alleviate the need for adult 
diapers, and 4-5 catheterizations a day proved sufficient 
to manage the urinary incontinence. She only 
experienced moderate pain after prolonged walking or 
standing and analgesia was satisfactorily achieved with 
acetaminophen.  
Upon discharge, she was able to walk (for Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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distances longer than 500 m) and climb stairs. We 
prescribed vitamin D, calcium, B complex supplements, 
neutrophics, acetaminophen, and we referred her to an 
endocrinology service for further assessment and 
treatment. 
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